These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 31053880)
21. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Calcinotto A; Ponzoni M; Ria R; Grioni M; Cattaneo E; Villa I; Sabrina Bertilaccio MT; Chesi M; Rubinacci A; Tonon G; Bergsagel PL; Vacca A; Bellone M Oncoimmunology; 2015 Jun; 4(6):e1008850. PubMed ID: 26155424 [TBL] [Abstract][Full Text] [Related]
22. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma. Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090 [TBL] [Abstract][Full Text] [Related]
23. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634 [TBL] [Abstract][Full Text] [Related]
24. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818 [TBL] [Abstract][Full Text] [Related]
25. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Fagerli UM; Holt RU; Holien T; Vaatsveen TK; Zhan F; Egeberg KW; Barlogie B; Waage A; Aarset H; Dai HY; Shaughnessy JD; Sundan A; Børset M Blood; 2008 Jan; 111(2):806-15. PubMed ID: 17934070 [TBL] [Abstract][Full Text] [Related]
26. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma. Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890 [TBL] [Abstract][Full Text] [Related]
27. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry. Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172 [TBL] [Abstract][Full Text] [Related]
28. Bone marrow eosinophils in plasma cell disorders. Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M Exp Hematol; 2018 Oct; 66():27-31.e5. PubMed ID: 29981782 [TBL] [Abstract][Full Text] [Related]
29. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311 [TBL] [Abstract][Full Text] [Related]
30. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183 [TBL] [Abstract][Full Text] [Related]
31. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study. Golombick T; Diamond TH; Manoharan A; Ramakrishna R Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182 [TBL] [Abstract][Full Text] [Related]
32. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295 [TBL] [Abstract][Full Text] [Related]
33. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957 [TBL] [Abstract][Full Text] [Related]
34. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Martín P; Santón A; Bellas C Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904 [TBL] [Abstract][Full Text] [Related]
35. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422 [TBL] [Abstract][Full Text] [Related]
36. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181 [TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487 [TBL] [Abstract][Full Text] [Related]
39. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020 [TBL] [Abstract][Full Text] [Related]
40. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G; Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]